ABSI · Absci
Conviction · Low · more likely to lag the S&P 500 over the next three months
Wrong if: a daily close above $12.25
Note written ·
Price against the kill line
31.0% clear of its kill line on the 13 November 2026 close.
How to read this
This note expects the shares to lag the market, so its kill line sits above the price: a close above the red mark would prove the view wrong. Prices run from low on the left to high on the right. The dot is where the stock closed on 13 November 2026, left of the mark while it is below the line; a dot right of the mark has closed through it.
The scale is stretched near the line, so close calls are easy to see. More than 8% from the line, the stock reads well clear, with a hollow dot to show the figure is off the drawn scale.
The kill line is the research note's own test. The portfolio sells on business facts, not on a price. How the portfolio decides
Three months against the kill line
Daily closes, to . Red: the kill line, a daily close above $12.25, on record since 11 November 2026. The shares are down 8.5% since the close; the S&P 500 is down 2.1% over the same sessions. Figures in the note can cover a different window.
Kill line
A daily close above $12.25, just under the $12.54 52-week intraday high of 29 October 2026, which would show the shares leading the S&P 500; or interim HEADLINE data showing a clear target-area hair-count gain over placebo.
Research onlyNot in the portfolio.
Catalyst
Key figures from the filings · Health Care
Quarter to 30 September 2026, filed 12 November 2026; valuation at the 13 November 2026 close
- Revenue, latest quarter ($M)
- 0.3
- Revenue, change on a year (%)
- −19.6
- Operating margin (%)
- −11511.2
- Net cash, cash less debt ($M)
- 174
- Enterprise value to sales (×)
- 864.9
All filed numbers
What Absci reports to the SEC in its quarterly and annual filings. Each group states its period and filing date once; a figure dated otherwise says so. Built from the filings known on .
| Quarter to | Revenue ($M) | On a year (%) | Operating margin (%) |
|---|---|---|---|
| first filed | 0.3 | −19.6 | −11511.2 |
| first filed | 0.3 | −46.4 | −10741.5 |
| first filed | 0.2 | −81.8 | −14347.0 |
| first filed | 0.7 | −2.3 | −4775.5 |
| first filed | 0.4 | −77.8 | −7977.2 |
| first filed | 0.6 | −53.3 | −5293.9 |
| Pre-tax income ($M) | −33.3 |
| Net income ($M) four quarters: −126 | −33.3 |
| Diluted shares, change on a year (%) against the quarter to 30 September 2025 | +19.5 |
| Operating cash flow ($M) | −113 |
| Capital spending ($M) | Not available |
| Free cash flow ($M) | Not available |
| Cash and short-term investments ($M) | 174 |
| Debt ($M) notes | 0.1 |
| Net cash, cash less debt ($M) | 174 |
| Deferred revenue ($M) −31.2% on a year | 1.1 |
| Backlog, orders not yet delivered ($M) | Not reported |
| Receivables ($M) at 30 September 2025, filed 12 November 2025 | 1.0 |
| Inventory ($M) | Not reported |
| Shareholders' equity ($M) | 219 |
| Market value ($M) | 1,460 |
| Enterprise value, market value plus net debt ($M) | 1,286 |
| Enterprise value to sales (×) | 864.9 |
| Enterprise value to operating income (×) | Not meaningful |
| Price to earnings (×) | Not meaningful |
| Price to book value (×) | 6.7 |
| Free-cash-flow yield (%) | Not available |
Short interest (FINRA, settled 15 October 2026, published 26 October 2026): 21.4% of shares outstanding sold short, 9.0 days of average trading to cover, −1.1% since the previous report.
| Window | Bought | Sold |
|---|---|---|
| 90 daysfrom | $0 | $0 |
| 12 monthsfrom | $933K | $132K |
The thesis
Absci Corporation's shares are more likely to lag the S&P 500 than lead it over the next three months. The price still assumes a good chance that its hair-loss antibody ABS-201 works, and the 13-week interim data from the HEADLINE trial, guided for December 2026, settle that question inside the window.
Absci's third-quarter release of 12 November 2026 narrowed the readout from "second half of 2026" to December 2026, with full 26-week data in early 2027. No day has been announced. These will be the first human hair-growth data for the drug. The June 2026 Phase 1 release covered blinded safety and drug-level data only, and the hair-regrowth evidence so far comes from mouse studies.
The shares fell on the day of the report. They closed at $9.13 on 12 November 2026, down from $10.12 the session before, per adjusted daily closes. That still leaves the price far above the 52-week closing low of $2.30 on 12 March 2026, a gain built on the hair-loss program alone. A result short of a clear hair-count gain over placebo would remove most of that premise. A clean win would prove this call wrong.
The rating is low because the deciding event now falls inside the three-month window, the mechanism is untested in human hair loss, and the price leaves more room to fall on a miss than to rise on a win already partly expected.
Bullish and bearish views on Absci Corporation
The bull case on Absci Corporation (ABSI), in brief: the readout now has a month. The bear case: efficacy in people is unproven.
Bull case
- The readout now has a month. On 12 November 2026, Absci guided interim HEADLINE data to December 2026 and said the trial is still dosing pattern hair-loss participants on track.
- Cash covers the readout and beyond. Cash, cash equivalents and marketable securities were $173.7 million at 30 September 2026, per the 10-Q filed 12 November 2026. Absci says this funds operating plans into the second half of 2028.
- Dosing could be infrequent. Blinded Phase 1 data from 32 healthy participants showed no serious adverse events and an estimated half-life of at least 65 days, per Absci's 24 June 2026 release. The company says this supports two or three injections over six months.
- The company is hiring for launch. On 12 November 2026, Absci appointed former Galderma executive Gerry Muhle as Chief Commercial Officer. Galderma is a dermatology and aesthetics company.
- A large drugmaker invested. Eli Lilly made a $40 million strategic investment in Absci's June 2026 share offering, per the company's second-quarter release of 11 August 2026. No licensing terms have been disclosed.
Bear case
- Efficacy in people is unproven. No human hair-count data exist yet. The December 2026 interim data are the first test of ABS-201's anti-prolactin-receptor mechanism in hair loss.
- Losses are rising. Third-quarter 2026 net loss was $33.3 million against $28.7 million a year earlier, per the 12 November 2026 release. Research and development spending rose to $23.6 million from $19.2 million.
- Revenue is negligible. Third-quarter revenue was $0.3 million, against a consensus estimate of about $0.73 million reported by Benzinga on 12 November 2026.
- The second program waits on the first. The Phase 2 STORYLINE endometriosis trial of about 150 patients is guided to start in mid-2027, per the 12 November 2026 release. The HEADLINE data inform its dosing.
- The market met the report with selling. The shares fell from a $10.12 close on 11 November 2026 to $9.13 on 12 November 2026, the day the results and the December timing were published.
Price setup
The shares closed at $9.13 on 12 November 2026, 27.2% below the 52-week intraday high of $12.54 set on 29 October 2026. The 3-month change is −0.5%, measured from the $9.18 close of 14 August 2026. The price has gone roughly nowhere over three months despite the run to the October high.
As of 12 November 2026, the 50-day moving average was $9.66 and the 200-day was $6.80. The 12 November 2026 close took the shares below the 50-day average for the first time in the recent run, while they remain well above the 200-day. Closes between 5 November 2026 and 12 November 2026 ranged from $9.13 to $10.80.
SEC Form 4 filings since August show only shares withheld for taxes on vesting awards, with no open-market sales. The largest was 79,860 shares withheld from Chief Executive Officer Sean McClain at $12.10 on 29 October 2026.
Catalysts ahead
- 18 November 2026: Jefferies Global Healthcare Conference (London) fireside chat, 10:00 a.m. ET. Management can confirm or move the December 2026 interim readout timing.
- 1 December 2026: Evercore Healthcare Conference fireside chat, 7:30 a.m. ET. Last scheduled management appearance before the guided December readout.
- ~31 December 2026 (est.): 13-week interim HEADLINE proof-of-concept data for ABS-201 in pattern hair loss, guided to December 2026; no day announced. A clear hair-count gain over placebo would prove the lag call wrong; a weak or missing result would confirm it.
- Early 2027 (est.): Full 26-week HEADLINE proof-of-concept data. Shows whether any interim effect holds or grows over six months and informs STORYLINE dosing.
What would change the view
A daily close above $12.25, just under the $12.54 52-week intraday high of 29 October 2026, which would show the shares leading the S&P 500; or interim HEADLINE data showing a clear target-area hair-count gain over placebo.
What it trades with
Absci trades on its own clinical event. Its swings through early November came mostly without company disclosures, and the largest single move came on the day of its own report. Into December, the HEADLINE readout should outweigh broad biotech sentiment as a driver. Eli Lilly's strategic stake ties the stock to large-drugmaker interest in the program, so partnering news is the likeliest company-specific driver after the readout.
The evidence, claim by claim (7)
- Absci anticipates reporting 13-week interim proof-of-concept data for ABS-201 in pattern hair loss in December 2026, with full 26-week data in early 2027. Absci third-quarter 2026 results release (8-K Exhibit 99.1), 12 November 2026 · as of
- Cash, cash equivalents and marketable securities were $173.7 million at 30 September 2026, down from $201.1 million at 30 June 2026; runway guided into the second half of 2028. Absci third-quarter 2026 10-Q and results release, 12 November 2026 · as of
- Third-quarter 2026 net loss was $33.3 million ($0.19 per share) against $28.7 million a year earlier; research and development spending rose to $23.6 million from $19.2 million; revenue was $0.3 million. Absci third-quarter 2026 results release, 12 November 2026 · as of
- Phase 2 STORYLINE endometriosis trial of ABS-201 planned with about 150 patients, two or three dose levels, initiation expected mid-2027. Absci third-quarter 2026 results release, 12 November 2026 · as of
- Absci appointed former Galderma executive Gerry Muhle as Chief Commercial Officer. Absci release, 12 November 2026 · as of
- Blinded interim Phase 1 data from 32 participants showed no serious adverse events and an estimated ABS-201 half-life of at least 65 days. Absci HEADLINE interim release, 24 June 2026 · as of
- CEO Sean McClain had 79,860 shares withheld for tax at $12.10; no open-market insider sales filed since August 2026. SEC Form 4, filed 30 October 2026 · as of
Sources
- Absci Corp - Form 8-K - FY2026 · sec.gov ·
- Absci Corp - Form 10-Q - FY2026 · sec.gov
- BioPharmaWatch ·
- investors.absci.com
- Absci Reports Business Updates and Second Quarter 2026 Financial and Operating Results · investors.absci.com
- Absci Corp Reports Q3 2026 Revenue of $0.3M, Net Loss Per Share of -$0.19, Missing Revenue Estimates · gurufocus.com
Related · shared themes
ZVRA
Zevra Therapeutics
Zevra Therapeutics is modestly more likely to beat the S&P 500 over three months: MIPLYFFA sold $34.0 million in the third quarter of 2026…
KOD
Kodiak Sciences
Kodiak Sciences' shares look more likely to lag the S&P 500 after a 161.8% three-month run that prices in the DAYBREAK win while share…
ABVX
Abivax SA
Abivax's shares are modestly more likely to beat the S&P 500 over three months because the company guides its US obefazimod ulcerative…
BHVN
Biohaven
Biohaven Ltd. is modestly more likely than not to beat the S&P 500 over three months: the SK Biopharmaceuticals licence has cleared US…